Moleculin Biotech ( (MBRX) ) has shared an update.
Moleculin Biotech, Inc. has begun treating patients in a Phase 2 study evaluating WP1066 for glioblastoma treatment, combining it with radiation therapy. The trial, funded by NIH and BrainUp, aims to address the high unmet need in brain cancer therapy, leveraging preclinical success that showed increased survival and immune response. With the FDA’s clearance, the study progresses under Northwestern University’s IND, marking a significant stride in cancer treatment research.
For a thorough assessment of MBRX stock, go to TipRanks’ Stock Analysis page.
